AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34205551 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily physical activity text message reminders (Intervention Group)
Number of subjects: 32
Study 34205551 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control Group)
Number of subjects: 32
Study 35328968 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation
Number of subjects: 91
Study 35328968 — intervention group
Group type: COMPARATOR
Intervention: Waiting control group
Number of subjects: 91
Study 33565825 — intervention group
Group type: EXPERIMENTAL
Intervention: Local administration of 80 mg of triamcinolone
Number of subjects: 60
Study 32079920 — intervention group
Group type: EXPERIMENTAL
Intervention: ENCAP (maltodextrin, fructose, sodium alginate, and pectin)
Number of subjects: 8
Study 32079920 — intervention group
Group type: EXPERIMENTAL
Intervention: POLY (maltodextrin and fructose)
Number of subjects: 8
Study 32079920 — intervention group
Group type: COMPARATOR
Intervention: MON (glucose and fructose)
Number of subjects: 8
Study 32079920 — intervention group
Group type: EXPERIMENTAL
Intervention: ENCAP vs MON
Number of subjects: 8
Study 32079920 — intervention group
Group type: EXPERIMENTAL
Intervention: ENCAP vs POLY
Number of subjects: 8
Study 32079920 — intervention group
Group type: EXPERIMENTAL
Intervention: All drinks
Number of subjects: 8
Study 35999237 — intervention group
Group type: COMPARATOR
Intervention: Care as usual during the control phase of the STARSHIP Trial
Number of subjects: 860
Study 33812198 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with MS (contracture)
Number of subjects: 40
Study 33812198 — intervention group
Group type: COMPARATOR
Intervention: Healthy participants
Number of subjects: 40
Study 32843079 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron isomaltoside (1000 mg)
Number of subjects: 200
Study 32843079 — intervention group
Group type: COMPARATOR
Intervention: Oral iron supplementation (100 mg ferrous fumarate with 60 mg ascorbic acid)
Number of subjects: 200
Study 34694277 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose metronidazole (2 g)
Number of subjects: 540
Study 34694277 — intervention group
Group type: COMPARATOR
Intervention: Multidose metronidazole (500 mg twice daily for 7 days)
Number of subjects: 540
Study 33622506 — intervention group
Group type: EXPERIMENTAL
Intervention: CBM-I sessions via the HabitWorks app during acute care and postdischarge
Number of subjects: 0
Study 33622506 — intervention group
Group type: EXPERIMENTAL
Intervention: HabitWorks app
Number of subjects: 0
Study 34714120 — intervention group
Group type: EXPERIMENTAL
Intervention: SDX/d-MPH (39.2 mg/7.8 mg/day, titrated to maximum dose of 52.3/10.4 mg)
Number of subjects: 149
Study 34714120 — intervention group
Group type: EXPERIMENTAL
Intervention: SDX/d-MPH
Number of subjects: 149
Study 34714120 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study 33247645 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab biosimilar
Number of subjects: 105
Study 33247645 — intervention group
Group type: COMPARATOR
Intervention: Reference product (Omalizumab)
Number of subjects: 105
Study 36336666 — intervention group
Group type: EXPERIMENTAL
Intervention: PROERD intervention (10 classes taught by trained police officers)
Number of subjects: 4030
Study 36336666 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 4030
Study 33592558 — intervention group
Group type: EXPERIMENTAL
Intervention: THC
Number of subjects: 46
Study 33592558 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 36442825 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT-ON arm
Number of subjects: 353
Study 33092632 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 Convalescent Plasma (CCP)
Number of subjects: 114
Study 33092632 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 114
Study 34839962 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole body vibration (WBV) training, 3 times a week for 3 months
Number of subjects: 50
Study 34839962 — intervention group
Group type: COMPARATOR
Intervention: Control group underwent multidisciplinary care for T2D
Number of subjects: 50
Study 34529503 — intervention group
Group type: EXPERIMENTAL
Intervention: Respecting the Circle of Life program (RCL)
Number of subjects: 534
Study 35135624 — intervention group
Group type: EXPERIMENTAL
Intervention: Public commitment charter
Number of subjects: 41
Study 35135624 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-prescription pad
Number of subjects: 41
Study 35135624 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient information leaflet
Number of subjects: 41
Study 33839309 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic excision of endometriotic foci and hysteroscopy with endometrial sampling
Number of subjects: 33
Study 33839309 — intervention group
Group type: COMPARATOR
Intervention: Endometrial sampling from control group
Number of subjects: 33
Study 35486015 — intervention group
Group type: EXPERIMENTAL
Intervention: Thunder-fire moxibustion combined with meibomian gland massage
Number of subjects: 72
Study 35486015 — intervention group
Group type: COMPARATOR
Intervention: 0.1% fluo‐rometholone eye drops and 0.1% sodium hyaluronate eye drops, 1-2 drops per time, four times per day, and meibomian gland massage once per day
Number of subjects: 72
Study 35613727 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA at weeks 0/8 + LIPO‐5 at weeks 20/28 (M/L)
Number of subjects: 92
Study 35613727 — intervention group
Group type: EXPERIMENTAL
Intervention: LIPO‐5 at weeks 0/8 + MVA at weeks 20/28 (L/M)
Number of subjects: 92
Study 35613727 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA at weeks 0/4/12 + LIPO‐5 at weeks 20/28 (G/L)
Number of subjects: 92
Study 35613727 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA at weeks 0/4/12 + MVA at weeks 20/28 (G/M)
Number of subjects: 92
Study 35613727 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA-receiving groups (M/L, L/M, G/M)
Number of subjects: 92
Study 35613727 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA-receiving groups (M/L, G/M)
Number of subjects: 92
Study 35613727 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA gene signature
Number of subjects: 92
Study 33656972 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide and sobuzoxane
Number of subjects: 0
Study 32820733 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotavirus positive samples
Number of subjects: 269
Study 35172742 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared Decision-Making (SDM) perceived by General Practitioners (GPs)
Number of subjects: 176
Study 35172742 — intervention group
Group type: COMPARATOR
Intervention: Shared Decision-Making (SDM) perceived by patients
Number of subjects: 176
Study 35172742 — intervention group
Group type: COMPARATOR
Intervention: Shared Decision-Making (SDM) perceived by external observers
Number of subjects: 176
Study 33255249 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glycemic index dietary intervention during pregnancy
Number of subjects: 63
Study 33255249 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 63
Study 35802649 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted therapies (TT) including selumetinib, vistusertib, capivasertib, AZD4547, AZD8931, vandetanib, olaparib, savolitinib
Number of subjects: 358
Study 35802649 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care
Number of subjects: 358
Study 35802649 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab
Number of subjects: 358
Study 35802649 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab in patients with PD-L1 TPS ≥1%
Number of subjects: 358
Study 35802649 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab in patients with PD-L1 <1%
Number of subjects: 358
Study 32628509 — intervention group
Group type: EXPERIMENTAL
Intervention: Phonomotor Therapy (PMT)
Number of subjects: 57
Study 32628509 — intervention group
Group type: COMPARATOR
Intervention: Semantic Feature Analysis (SFA)
Number of subjects: 57
Study 2010501984 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermacyn
Number of subjects: 178
Study 2010501984 — intervention group
Group type: COMPARATOR
Intervention: Povidone-iodine
Number of subjects: 178
Study 34542221 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide 10 mg
Number of subjects: 0
Study 34542221 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide 15 mg
Number of subjects: 0
Study 34542221 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34542221 — intervention group
Group type: COMPARATOR
Intervention: Dulaglutide 1.5 mg
Number of subjects: 0
Study 33568628 — intervention group
Group type: EXPERIMENTAL
Intervention: UC-MSCs (4×10^7 cells per infusion)
Number of subjects: 100
Study 33568628 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 34268829 — intervention group
Group type: EXPERIMENTAL
Intervention: Active participation in nursing handover
Number of subjects: 33
Study 34268829 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive participation in nursing handover
Number of subjects: 33
Study 34268829 — intervention group
Group type: EXPERIMENTAL
Intervention: No input in nursing handover
Number of subjects: 33
Study 34268829 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors influencing active participation
Number of subjects: 33
Study 34268829 — intervention group
Group type: EXPERIMENTAL
Intervention: Themes from interviews
Number of subjects: 33
Study 33348282 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher food prices
Number of subjects: 3473
Study 33348282 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher neighborhood poverty
Number of subjects: 3473
Study 33348282 — intervention group
Group type: EXPERIMENTAL
Intervention: Policies and programs addressing food prices
Number of subjects: 3473
Study 32511165 — intervention group
Group type: EXPERIMENTAL
Intervention: Welch Allyn SureSight
Number of subjects: 21
Study 32511165 — intervention group
Group type: EXPERIMENTAL
Intervention: Plusoptix PowerRefractor
Number of subjects: 21
Study 32511165 — intervention group
Group type: COMPARATOR
Intervention: Grand Seiko WR‐5100K
Number of subjects: 21
Study 35105533 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple antithrombotic therapy (TAT)
Number of subjects: 209
Study 35105533 — intervention group
Group type: COMPARATOR
Intervention: Double antithrombotic therapy (DAT)
Number of subjects: 209
Study 32311976 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy combined with Jianpi Yangzheng Xiaozheng decoction (JPYZXZ)
Number of subjects: 210
Study 32311976 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 210
Study 36174930 — intervention group
Group type: EXPERIMENTAL
Intervention: 50mg losartan
Number of subjects: 87
Study 36174930 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 33252090 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized semi-supervised home-based exercise program (3 times a week for 10 weeks)
Number of subjects: 0
Study 33252090 — intervention group
Group type: COMPARATOR
Intervention: Assistive training device
Number of subjects: 0
Study 32979907 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical atorvastatin 5% cream plus topical betamethasone 1% ointment
Number of subjects: 88
Study 32979907 — intervention group
Group type: COMPARATOR
Intervention: Topical betamethasone 1% ointment plus vehicle cream
Number of subjects: 88
Study 34971258 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive stimulation virtual therapy (CSVT) program, 6 months, 2 sessions per week (N = 10)
Number of subjects: 20
Study 34971258 — intervention group
Group type: COMPARATOR
Intervention: Active control group (N = 10)
Number of subjects: 20
Study 34971258 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive stimulation virtual therapy (CSVT) program
Number of subjects: 20
Study 32977212 — intervention group
Group type: EXPERIMENTAL
Intervention: Active multifocal tDCS (20 min, 1 mA per electrode, using 4 anodes and 4 cathodes)
Number of subjects: 46
Study 32977212 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 46
Study 35687761 — intervention group
Group type: EXPERIMENTAL
Intervention: lacutamab (anti-KIR3DL2 humanized antibody)
Number of subjects: 71
Study 35687761 — intervention group
Group type: EXPERIMENTAL
Intervention: KIR3DL2 expression
Number of subjects: 71
Study 35687761 — intervention group
Group type: EXPERIMENTAL
Intervention: HTLV-1 infection
Number of subjects: 71
Study 35687761 — intervention group
Group type: EXPERIMENTAL
Intervention: KIR3DL2 and TAX mRNA expression levels
Number of subjects: 71
Study 35687761 — intervention group
Group type: EXPERIMENTAL
Intervention: KIR3DL2 promoter demethylation
Number of subjects: 71
Study 34132506 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-0 polyglycolic acid sutures
Number of subjects: 62
Study 34132506 — intervention group
Group type: COMPARATOR
Intervention: 3-0 black silk sutures
Number of subjects: 62
Study 32432798 — intervention group
Group type: EXPERIMENTAL
Intervention: Tildrakizumab (IL-23p19 inhibitor)
Number of subjects: 0
Study 32432798 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35902155 — intervention group
Group type: EXPERIMENTAL
Intervention: Kansas City Cardiomyopathy Questionnaire (KCCQ)
Number of subjects: 196
Study 34931372 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyzetimibe (HS‐25)
Number of subjects: 24
Study 32502991 — intervention group
Group type: EXPERIMENTAL
Intervention: RECO Flow Restoration Device
Number of subjects: 136
Study 32502991 — intervention group
Group type: COMPARATOR
Intervention: Solitaire FR
Number of subjects: 136
Study 34427473 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant factor VIIa (rFVIIa) 80 µg/kg intravenously over 2 min
Number of subjects: 860
Study 34427473 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 860
Study 34427473 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant factor VIIa (rFVIIa)
Number of subjects: 860
Study 34159708 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 3.0 mg
Number of subjects: 1842
Study 34159708 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 4.5 mg
Number of subjects: 1842
Study 34159708 — intervention group
Group type: COMPARATOR
Intervention: Dulaglutide 1.5 mg
Number of subjects: 1842
Study 34159708 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite endpoint (HbA1c < 7% with no weight gain and no documented symptomatic or severe hypoglycaemia)
Number of subjects: 1842
Study 34159708 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety profile
Number of subjects: 1842
Study 32610647 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent Hypoxic Exposure (IHE)
Number of subjects: 38
Study 32610647 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine (2 × 6 g/day) with IHE
Number of subjects: 38
Study 32610647 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 32610647 — intervention group
Group type: EXPERIMENTAL
Intervention: IHE and Arg/IHE
Number of subjects: 38
Study 34253099 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions related to maintaining/improving resident function, providing adequate nurse staffing levels, and improving staff communication skills.
Number of subjects: 536
Study 34253099 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 536
Study 33545090 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Number of subjects: 314
Study 33545090 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial viral load
Number of subjects: 314
Study 35688515 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral QLB
Number of subjects: 111
Study 35688515 — intervention group
Group type: COMPARATOR
Intervention: LPB
Number of subjects: 111
Study 32586363 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (200 mg tablet every other day for 2 months)
Number of subjects: 60
Study 32586363 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical in terms of shape, colour, smell, 200 mg tablet every other day for 2 months)
Number of subjects: 60
Study 35489606 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccine
Number of subjects: 1511
Study 35489606 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1511
Study 34876630 — intervention group
Group type: EXPERIMENTAL
Intervention: RAM cannula with Cannulaide
Number of subjects: 229
Study 34876630 — intervention group
Group type: COMPARATOR
Intervention: Hudson prong
Number of subjects: 229
Study 89155066 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 120
Study 89155066 — intervention group
Group type: COMPARATOR
Intervention: Chlordiazepoxide and chlorpromazine combination
Number of subjects: 120
Study 35611641 — intervention group
Group type: EXPERIMENTAL
Intervention: CDS displaying NEWT
Number of subjects: 2682
Study 35611641 — intervention group
Group type: COMPARATOR
Intervention: Control (usual care with NEWT accessed at clinician discretion)
Number of subjects: 2682
Study 34143564 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous IV sildenafil
Number of subjects: 43
Study 34143564 — intervention group
Group type: COMPARATOR
Intervention: Intermittent IV sildenafil
Number of subjects: 43
Study 34143564 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 43
Study 32016532 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylnaltrexone
Number of subjects: 84
Study 32016532 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 32379241 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoinertial training
Number of subjects: 34
Study 32379241 — intervention group
Group type: COMPARATOR
Intervention: Cable-resistance training
Number of subjects: 34
Study 32379241 — intervention group
Group type: EXPERIMENTAL
Intervention: Both training programs
Number of subjects: 34
Study 33846472 — intervention group
Group type: EXPERIMENTAL
Intervention: Convolutional Neural Network (CNN) model using brain MRI data
Number of subjects: 221
Study 34076602 — intervention group
Group type: EXPERIMENTAL
Intervention: Periprocedural myocardial infarction (MI)
Number of subjects: 586
Study 34076602 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with periprocedural MI
Number of subjects: 586
Study 34076602 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 586
Study 34793989 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetable intervention (8-week feeding phase with DGA-recommended types and amounts of vegetables)
Number of subjects: 75
Study 34793989 — intervention group
Group type: COMPARATOR
Intervention: Attention control group (no vegetables provided, same testing schedule)
Number of subjects: 75
Study 33434493 — intervention group
Group type: EXPERIMENTAL
Intervention: moPMR‐Egger (multiple outcome probabilistic Mendelian randomization with Egger assumption)
Number of subjects: 0
Study 33434493 — intervention group
Group type: EXPERIMENTAL
Intervention: moPMR‐Egger
Number of subjects: 0
Study 34420924 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone app (Prepit, Ferring B V)
Number of subjects: 173
Study 34420924 — intervention group
Group type: COMPARATOR
Intervention: Control group (regular written instructions)
Number of subjects: 173
Study 32738588 — intervention group
Group type: EXPERIMENTAL
Intervention: Updated version of the Behaviour of Young Novice Drivers Scale (BYNDS)
Number of subjects: 700
Study 34313502 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-care intervention (N = 52)
Number of subjects: 95
Study 34313502 — intervention group
Group type: COMPARATOR
Intervention: Passive control condition (N = 43)
Number of subjects: 95
Study 32815386 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture plus warm needling (EAWN) therapy
Number of subjects: 80
Study 32815386 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control (no treatment)
Number of subjects: 80
Study 33175132 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose (HD) IIV followed by standard dose (SD) vaccine (HD-SD arm)
Number of subjects: 68
Study 33175132 — intervention group
Group type: COMPARATOR
Intervention: Standard dose (SD) vaccines (SD-SD arm)
Number of subjects: 68
Study 33175132 — intervention group
Group type: EXPERIMENTAL
Intervention: Both HD-SD and SD-SD arms
Number of subjects: 68
Study 32910434 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab 100 mg every 8 weeks
Number of subjects: 992
Study 35120040 — intervention group
Group type: EXPERIMENTAL
Intervention: External warming using a forced-air warming blanket for 48 hours, goal temperature 1.5°C above the lowest temperature documented in the previous 24 hours.
Number of subjects: 56
Study 35120040 — intervention group
Group type: COMPARATOR
Intervention: Standard temperature management (control group).
Number of subjects: 56
Study 35120040 — intervention group
Group type: EXPERIMENTAL
Intervention: External warming using a forced-air warming blanket for 48 hours.
Number of subjects: 56
Study 33012264 — intervention group
Group type: EXPERIMENTAL
Intervention: Black participants
Number of subjects: 184
Study 33012264 — intervention group
Group type: EXPERIMENTAL
Intervention: Income mediation
Number of subjects: 184
Study 33012264 — intervention group
Group type: EXPERIMENTAL
Intervention: Difficulty paying monthly bills mediation
Number of subjects: 184
Study 33012264 — intervention group
Group type: EXPERIMENTAL
Intervention: Health literacy mediation
Number of subjects: 184
Study 33012264 — intervention group
Group type: EXPERIMENTAL
Intervention: Education mediation
Number of subjects: 184
Study 32812033 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplemented at 2,200 IU/kg of dietary DM
Number of subjects: 30
Study 32812033 — intervention group
Group type: COMPARATOR
Intervention: Vitamin A supplemented at 0 IU/kg of dietary DM (Control)
Number of subjects: 30
Study 32812033 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplemented at 11,000 IU/kg of dietary DM
Number of subjects: 30
Study 34728061 — intervention group
Group type: EXPERIMENTAL
Intervention: D-series resolvins (D1, D2, D3, D5), resolvin E1, maresin 1, docosahexaenoic acid, eicosapentaenoic acid, 18-hydroxyeicosapentaenoic acid
Number of subjects: 31
Study 34728061 — intervention group
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid and 18-hydroxyeicosapentaenoic acid
Number of subjects: 31
Study 32649760 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus 30-g dose of LNS
Number of subjects: 26